Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 12 studies | 32% ± 14% | |
plasma cell | 9 studies | 32% ± 11% | |
plasmablast | 7 studies | 45% ± 26% | |
regulatory T cell | 7 studies | 19% ± 3% | |
natural killer cell | 6 studies | 19% ± 3% | |
CD8-positive, alpha-beta T cell | 6 studies | 17% ± 2% | |
epithelial cell | 4 studies | 22% ± 5% | |
non-classical monocyte | 3 studies | 19% ± 3% | |
dendritic cell | 3 studies | 38% ± 4% | |
effector CD8-positive, alpha-beta T cell | 3 studies | 22% ± 3% | |
CD4-positive, alpha-beta T cell | 3 studies | 16% ± 1% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 17% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 583.89 | 1445 / 1445 | 100% | 10.97 | 183 / 183 |
ovary | 100% | 592.59 | 180 / 180 | 100% | 7.27 | 430 / 430 |
stomach | 100% | 456.78 | 359 / 359 | 100% | 11.32 | 286 / 286 |
uterus | 100% | 682.00 | 170 / 170 | 100% | 11.79 | 459 / 459 |
thymus | 100% | 545.73 | 653 / 653 | 100% | 8.77 | 604 / 605 |
lung | 100% | 623.18 | 578 / 578 | 100% | 10.62 | 1153 / 1155 |
intestine | 100% | 635.72 | 966 / 966 | 100% | 12.18 | 526 / 527 |
skin | 100% | 802.60 | 1809 / 1809 | 100% | 22.38 | 471 / 472 |
liver | 100% | 2475.56 | 226 / 226 | 100% | 21.91 | 405 / 406 |
breast | 100% | 579.67 | 459 / 459 | 100% | 11.20 | 1114 / 1118 |
bladder | 100% | 890.76 | 21 / 21 | 100% | 11.11 | 502 / 504 |
prostate | 100% | 605.51 | 245 / 245 | 100% | 8.63 | 500 / 502 |
kidney | 100% | 956.36 | 89 / 89 | 99% | 11.02 | 893 / 901 |
pancreas | 99% | 467.87 | 326 / 328 | 99% | 9.65 | 177 / 178 |
brain | 98% | 308.65 | 2589 / 2642 | 100% | 8.24 | 705 / 705 |
adrenal gland | 100% | 721.39 | 258 / 258 | 95% | 7.41 | 219 / 230 |
adipose | 100% | 534.92 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 21.63 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 22.30 | 29 / 29 |
spleen | 100% | 1135.66 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 9.40 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.95 | 1 / 1 |
muscle | 100% | 528.26 | 802 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 510.26 | 1333 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1074.47 | 916 / 929 | 0% | 0 | 0 / 0 |
heart | 98% | 425.62 | 846 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000288 | Biological process | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay |
GO_0045292 | Biological process | mRNA cis splicing, via spliceosome |
GO_0000290 | Biological process | deadenylation-dependent decapping of nuclear-transcribed mRNA |
GO_0110156 | Biological process | mRNA methylguanosine-cap decapping |
GO_0000932 | Cellular component | P-body |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0005634 | Cellular component | nucleus |
GO_0140932 | Molecular function | 5'-(N(7)-methyl 5'-triphosphoguanosine)-[mRNA] diphosphatase activity |
GO_0000340 | Molecular function | RNA 7-methylguanosine cap binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0004532 | Molecular function | RNA exonuclease activity |
Gene name | DCPS |
Protein name | m7GpppX diphosphatase (EC 3.6.1.59) (DCS-1) (Decapping scavenger enzyme) (Hint-related 7meGMP-directed hydrolase) (Histidine triad nucleotide-binding protein 5) (Histidine triad protein member 5) (HINT-5) (Scavenger mRNA-decapping enzyme DcpS) m7GpppX diphosphatase (EC 3.6.1.59) (DCS-1) (Decapping scavenger enzyme) (Hint-related 7meGMP-directed hydrolase) (Histidine triad nucleotide-binding protein 5) (Histidine triad protein member 5) (Scavenger mRNA-decapping enzyme DcpS) m7GpppX diphosphatase (EC 3.6.1.59) |
Synonyms | hCG_39127 HSPC015 DCS1 HINT5 |
Description | FUNCTION: Decapping scavenger enzyme that catalyzes the cleavage of a residual cap structure following the degradation of mRNAs by the 3'->5' exosome-mediated mRNA decay pathway. Hydrolyzes cap analog structures like 7-methylguanosine nucleoside triphosphate (m7GpppG) with up to 10 nucleotide substrates (small capped oligoribonucleotides) and specifically releases 5'-phosphorylated RNA fragments and 7-methylguanosine monophosphate (m7GMP). Cleaves cap analog structures like tri-methyl guanosine nucleoside triphosphate (m3(2,2,7)GpppG) with very poor efficiency. Does not hydrolyze unmethylated cap analog (GpppG) and shows no decapping activity on intact m7GpppG-capped mRNA molecules longer than 25 nucleotides. Does not hydrolyze 7-methylguanosine diphosphate (m7GDP) to m7GMP . May also play a role in the 5'->3 mRNA decay pathway; m7GDP, the downstream product released by the 5'->3' mRNA mediated decapping activity, may be also converted by DCPS to m7GMP . Binds to m7GpppG and strongly to m7GDP. Plays a role in first intron splicing of pre-mRNAs. Inhibits activation-induced cell death. . FUNCTION: Decapping scavenger enzyme that catalyzes the cleavage of a residual cap structure following the degradation of mRNAs by the 3'->5' exosome-mediated mRNA decay pathway. . |
Accessions | ENST00000648516.1 ENST00000263579.5 Q96C86 A0A384MTI8 A0A3B3ITF0 |